Differences between normal and CML stem cells: potential targets for clinical exploitation - PubMed (original) (raw)
Review
. 1998:16 Suppl 1:77-83; discussion 89.
doi: 10.1002/stem.5530160809.
Affiliations
- PMID: 11012149
- DOI: 10.1002/stem.5530160809
Review
Differences between normal and CML stem cells: potential targets for clinical exploitation
A C Eaves et al. Stem Cells. 1998.
Abstract
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder in which there is a deregulated amplification of CML progenitors at intermediate stages of their differentiation along the myeloid, erythroid and megakaryocyte pathways. Such cell populations are routinely quantified using standard in vitro colony-forming cell (CFC) assays. The excessive production of leukemic CFC that is seen in most CML patients at diagnosis may be explained at least in part by their increased proliferative activity. An anomalous cycling behavior in vivo has also been found to extend to more primitive CML progenitor populations detectable as long-term culture-initiating cells (LTC-IC). Although the molecular basis of these changes in CML progenitor regulation is not fully understood at the level of the primitive CFC compartment, a selective inability of CML progenitors to be inhibited by certain -C-C-type chemokines has been demonstrated. Failure of the CML stem cell compartment to expand in vivo at the same rate as later progenitor cell types may be explained by their unique additional possession of an intrinsically upregulated probability of differentiation. Such a mechanism would be consistent with the observed loss of LTC-IC activity by CML cells incubated in vitro under conditions that sustain or expand normal LTC-IC populations. Initial clinical studies undertaken at our center established the feasibility of exploiting the differential behavior of primitive normal and CML cells in vitro as a potential purging strategy for reducing the leukemic stem cell content of CML marrow autografts. The results of a larger, second trial now in progress on a group of unselected patients are encouraging. Future studies of nonobese diabetic/severe-combined immunodeficiency mice engrafted with CML cells should provide another useful preclinical model for evaluating treatments that may more effectively eradicate the neoplastic clone in vivo.
Similar articles
- Biological strategies for the selective manipulation of normal and leukemic stem cells.
Eaves CJ, Cashman JD, Zoumbos NC, Barnett MJ, Eaves AC. Eaves CJ, et al. Stem Cells. 1993 Oct;11 Suppl 3:109-21. doi: 10.1002/stem.5530110924. Stem Cells. 1993. PMID: 7905319 Review. - The human hematopoietic stem cell in vitro and in vivo.
Eaves CJ, Sutherland HJ, Udomsakdi C, Lansdorp PM, Szilvassy SJ, Fraser CC, Humphries RK, Barnett MJ, Phillips GL, Eaves AC. Eaves CJ, et al. Blood Cells. 1992;18(2):301-7. Blood Cells. 1992. PMID: 1360270 Clinical Trial. - Lhx2 expression in hematopoietic progenitor/stem cells in vivo causes a chronic myeloproliferative disorder and altered globin expression.
Richter K, Pinto do O P, Hägglund AC, Wahlin A, Carlsson L. Richter K, et al. Haematologica. 2003 Dec;88(12):1336-47. Haematologica. 2003. PMID: 14687986 - Differential manipulation of normal and chronic myeloid leukemia stem cell proliferation in vitro.
Eaves C, Eaves A. Eaves C, et al. Blood Cells. 1994;20(1):83-93; discussion 93-5. Blood Cells. 1994. PMID: 7994064 Review.
Cited by
- High BCR::ABL1 Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Proliferative Potential and Self-Renewal Ability.
Massimino M, Stella S, Tirrò E, Pennisi MS, Stagno F, Vitale SR, Romano C, Tomarchio C, Parrinello NL, Manzella L, Di Raimondo F, Vigneri P. Massimino M, et al. Onco Targets Ther. 2023 Oct 3;16:803-816. doi: 10.2147/OTT.S413825. eCollection 2023. Onco Targets Ther. 2023. PMID: 37807980 Free PMC article. - Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy.
Abe A, Minami Y, Hayakawa F, Kitamura K, Nomura Y, Murata M, Katsumi A, Kiyoi H, Jamieson CHM, Wang JYJ, Naoe T. Abe A, et al. Int J Hematol. 2008 Dec;88(5):471-475. doi: 10.1007/s12185-008-0221-1. Epub 2008 Nov 29. Int J Hematol. 2008. PMID: 19039626 Free PMC article. - Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy.
Chomel JC, Turhan AG. Chomel JC, et al. Oncotarget. 2011 Sep;2(9):713-27. doi: 10.18632/oncotarget.333. Oncotarget. 2011. PMID: 21946665 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical